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Background:  Paediatric  Crohn’s  disease  patients  suffer  from  several  complications,  including  low  bone
mineral  density  and  inadequate  serum  levels  of  25-hydroxy  vitamin  D.
Aims:  The  aim  of this  prospective  study  was  to address  the  effect  of inﬂiximab  therapy  on  bone
metabolism,  bone  mineral  density  and  vitamin  D  homeostasis.  The  seasonal  variability  of serum  vitamin
D levels  in relation  to inﬂiximab  treatment  was  also  analysed.
Methods:  Serum  osteocalcin  and  beta-crosslaps  (markers  of bone  metabolism),  seasonal  variability  of
vitamin  D, and  bone  mineral  density  were  assessed  and  followed  throughout  the  yearlong  treatment
regimen  of inﬂiximab  in  50 consecutive  paediatric  patients  with  moderate  to  severe  Crohn’s  disease.
Results:  Bone  forming  osteocalcin  levels  were  signiﬁcantly  (p < 0.001)  increased  during  inﬂiximab  therapy.
In contrast,  no  signiﬁcant  changes  in  beta-crosslaps  and  vitamin  D  levels  were  observed.  Vitamin  D  levels
were  signiﬁcantly  different  when  the  summer  and  winter  periods  were  compared  at week  0 (p = 0.039);
however,  this  difference  was  not  detected  after  one  year  of  inﬂiximab  therapy.  Despite  the  beneﬁcial
clinical  effect  of  inﬂiximab,  there  was  no  signiﬁcant  change  in bone  mineral  density  Z-scores  after  one
year  of treatment.
Conclusion:  Inﬂiximab  may  beneﬁcially  affect  bone  homeostasis.  Moreover,  seasonal  variability  in  vitamin
D levels  observed  prior  to  initiation  of  inﬂiximab  treatment  was  diminished  after  one  year  of treatment.
© 2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
Crohn’s disease (CD) is a chronic inﬂammatory bowel disease
IBD) condition affecting the gastrointestinal tract. There is an
ncreasing incidence of CD in childhood, which has thus contributed
o an increased number of affected children [1,2]. Chronic intestinal
nﬂammation leads to low bone mineral density (BMD), a frequent
omplication in both children and adults with CD [3,4]. It has been
ypothesized that low BMD  in CD occurs either because of the dis-
ase itself or due to the therapeutics used. Abnormalities in BMD,
∗ Corresponding author at: 1st Department of Pediatrics, Semmelweis University,
3  Bókay Street, 1083 Budapest, Hungary. Tel.: +36 1 3343743; fax: +36 1 3036077.
E-mail address: veres.gabor@med.semmelweis-univ.hu (G. Veres).
ttp://dx.doi.org/10.1016/j.dld.2015.05.006
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allwhich can be evaluated by densitometry, can also be analysed by
biochemical markers of bone turnover such as osteocalcin, a marker
of bone formation, and -isomerized C-terminal telopeptide frag-
ments of collagen type I (beta-CrossLaps or bCL), an indicator of
bone resorption [5].
In addition to inﬂammation, several other mechanisms have
been implicated in CD-related reduction of BMD, such as malab-
sorption and malnutrition, genetics, drug therapy (e.g. corticos-
teroids), low dietary intake of essential vitamins (e.g. 25-hydroxy
vitamin D), and a lack of physical activity. Release of chronic
pro-inﬂammatory cytokines plays a pivotal role in the regulation
and maintenance of bone health. Tumour necrosis factor alpha
(TNF-), interleukin-1  (IL-1) and IL-6 stimulate bone resorp-
tion through a balanced modulation of osteoclast and osteoblast
activation and differentiation [6,7]. While previous studies have
 rights reserved.
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mplicated corticosteroids in impaired BMD  [8], other treatments
ave been shown to have a beneﬁcial effect on bone through reg-
lation of pro-inﬂammatory cytokines. Inﬂiximab (IFX), a chimeric
onoclonal antibody therapeutic targeted against TNF-, may
mprove bone mineralization [9]. Several different mechanisms
ontribute to the positive effects of IFX. While IFX-mediated reduc-
ion of pro-inﬂammatory cytokines, such as TNF-, IL-6 and IL-1,
epresent an important mode of action [10,11], the IFX-induced
eduction in gut inﬂammation also promotes improved absorption
f critical bone nutrients such as vitamin D and calcium. More-
ver, an improvement in patient health leads to increased physical
ctivity, which may  also lead to an increase bone formation [6].
Vitamin D is an essential nutrient required for proper bone
ineralization. Vitamin D has also been shown to regulate the
mmune system due to its indispensable role in the development
f self-tolerance. Studies in animal and in vitro models have shown
hat vitamin D functions in the formation of a normal immune
esponse and enhancement of cytokine production [12,13]. Recent
tudies have revealed a higher prevalence of vitamin D deﬁciency
n adults and children with IBD [3,14]. The beneﬁts of vitamin D
ndicate that it may  be an additional treatment option in CD. An
arlier study, however, demonstrated conﬂicting results when CD
atients with low BMD  were treated with calcium and vitamin D
15].
Vitamin D levels ﬂuctuate with the different seasons of the year.
he late winter months are associated with lower vitamin D levels
oth in healthy individuals and IBD patients [13,16,17]. The effect
f seasons on vitamin D levels in patients receiving IFX therapy,
owever, has not yet been studied.
The primary aim of this study was to evaluate the effect of IFX
reatment on clinical parameters, bone metabolism, bone mineral
ensity, and vitamin D homeostasis in moderate to severe paedi-
tric CD patients. We  also provide a characterization of the seasonal
ariability of vitamin D levels at baseline and follow-up in our
atient population.
. Patients and methods
.1. Patients
Our prospective study was performed in the 1st Department
f Paediatrics of Semmelweis University from January 2009 to
ecember 31, 2013. Fifty children with moderate to severe CD
ho were resistant to conventional therapy (azathioprine, sys-
emic steroids) and had a Paediatric Crohn’s Disease Activity Index
PCDAI) >30 were included in the analysis of vitamin D level, bone
arkers and BMD  changes during the yearlong IFX therapy. To
onitor the seasonal changes of serum vitamin D levels, an addi-
ional 25 children with CD who were treated with IFX were included
only the vitamin D serum level was available).
Inclusion criteria were resistance to conventional therapy for at
east three months following their diagnosis, a PCDAI score higher
han 30 when IFX therapy was initiated, and vitamin D supplemen-
ation for at least three months prior to IFX therapy. Administration
f azothiprine or steroids was not grounds for exclusion.
Control group. A control group containing 34 children with CD
n clinical and IFX-free (PCDAI≤12.5) remission was also included
n this study. Vitamin D serum level was measured in every patient
rom the control group. Additionally, 14 patients were also eval-
ated for osteocalcin and bCL levels. In the patients analysed for
steocalcin and bCL levels, steroid treatment was not allowed as a
orm of remission induction.
Written, informed consent was obtained from parents prior to
tudy enrollment. The study was approved by the Semmelweis Uni-
ersity Regional and Institutional Committee and Research Ethics. Disease 47 (2015) 652–657 653
2.2. Methods
Vitamin D and calcium supplementation. During treatment,
patients (IFX and control groups) received 1000 U/day vitamin D
and 500 mg/day calcium supplements.
Patients in the IFX treatment group received a 5 mg/kg intra-
venous infusion of IFX as an induction therapy at week 0, 2 and 6,
and as a maintenance therapy at every following 8th week, based
on the guidelines for IFX treatment in paediatric CD [18].
IMPACT-III and PCDAI. To measure health-related quality of life
(QoL) the IMPACT-III questionnaire – developed by Otley et al. and
validated in Hungary – was  administered to patients. IMPACT-III is a
self-reported questionnaire consisting of 35 queries. On a ﬁve point
Likert scale, children indicated the extent to which they belong to
each query by speciﬁc aspects of their health condition. IMPACT-
III scores range from 35 to 175, with a higher score indicative of a
better QoL [19,20]. In addition, PCDAI was evaluated and followed
over time [21].
Bone markers and vitamin D. Levels of serum osteocalcin and bCL,
markers of bone metabolism and bone turnover respectively, and
25-hydroxicholecalciferol (vitamin D) quantity were measured at
week 0, week 6, week 30 and week 53. Blood samples were collected
by venepuncture into a vacutainer tube with no additive, and the
serums were processed before the IFX treatment started. Samples
for the vitamin D analysis were protected from sunlight and were
post-processed within a few hours of collection from the patient. A
standard consensus regarding the normal range of vitamin D levels
has not yet been established. Using the recent guidelines estab-
lished by the Endocrine Society in 2011, vitamin D deﬁciency was
deﬁned as ≤20 ng/mL while vitamin D insufﬁciency was  deﬁned as
21–29 ng/mL [16,22].
Based on the date of the ﬁrst IFX therapy, seasonal variability of
vitamin D level was  measured. The summer period was designated
as the 21st of March through 22nd of September while the rest of
the year was designated the winter period.
Procedures. Immunoassay analyses were carried out with elec-
trochemiluminescence immunoassay (ECLIA) methods (Elecsys
N-MID Osteocalcin and Elecsys beta-CrossLaps, Roche®) and with
a chemiluminescence immunoassay (25-OH Vitamin D, LIAISON®,
DiaSorin), which were performed according to the manufacturer’s
instructions.
Whole-body and lumbar spine Dual-energy X-ray absorptiome-
try (DEXA) (type: QDR Discovery, model: Discovery A (S/N 83638),
HOLOGIC, Inc., USA) scans were used primarily to evaluate BMD
status before IFX treatment and at the conclusion of one year
of IFX treatment. All scans were performed by the same opera-
tor. The scan provided measurements of lumbar and whole-body
area BMD  (g/cm2). Z-scores were calculated by subtracting the
standard deviation of measured BMD  from the expected BMD
of individuals of the same age and sex. A Z-score <−2.0 was
reported as reduced bone mineral mass [23]. Whole-body DEXA
measurements served as a readout for cortical bone health,
whereas lumbar spine DEXA served as an assessment of trabecular
bone.
2.3. Statistics
All analyses were performed using SPSS 22 (IBM®, Somers, NY)
statistical software. Based on the results of Kolmogorow–Smirnov
and Shapiro–Wilk normality tests, the PCDAI, IMPACT-III, bone
markers and vitamin D data sets followed a non-normal distribu-
tion. The BMD  data showed a normal distribution. To determine
signiﬁcance, the Friedman test was used as a non-parametric test
and a paired t-test was used as a parametric probe. A p-value of
<0.05 was set as the threshold for statistical signiﬁcance. Pair-
wise comparisons were performed with a Bonferroni correction for
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Table 1
Characteristics of the study population.
Total number of patients 50
Male gender (%) 19 (38)
Mean age; years (±SD) 14.8 (±2.4)
Mean disease duration: years (±SD) 2.1 (±2.0)
Medical treatment when IFX therapy was introduced; n (%)
Azathioprine + 5-ASA + steroid + antibiotic 3 (6)
Azathioprine + 5-ASA + steroid 9 (18)
(4 methilprednisolone,
5 budesonide)
Azathioprine + 5-ASA + antibiotic 3 (6)
Azathioprine + 5-ASA 24 (48)
Azathioprine + steroid 1 (2)
Azathioprine + antibiotic 1 (2)
5-ASA + antibiotic 2 (4)
5-ASA + steroid 2 (4)
Azathioprine 2 (4)
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centage increased to 22% by week 53 (Fig. 2). In the control group,
25% of patients had a vitamin D deﬁciency and 21% had vitamin D
level >29 ng/mL (Table 2). When vitamin D levels were compared
0%
20%
40%
60%
80%
100%
Adatsor4
>29 ng/ml
20-29 ng/ml
20 ng/ml≤5-ASA 3 (6)
-ASA: 5-aminosalicylic acid, IFX: inﬂiximab.
ultiple comparisons. A p-value of 0.01 was considered statistically
igniﬁcant.
To determine the correlation between the laboratory and
linical parameters, the Spearman correlation coefﬁcient was cal-
ulated.
. Results
.1. Patient data
The IFX group included 50 children (38% males, mean age
4.8 ± 2.4 years, range 8–18.6). The mean elapsed time since diag-
osis was 2.1 ± 2.1 years (Table 1).
The control group included 34 children (55.8% males, mean
ge 14.5 ± 3.6 years). The mean elapsed time since diagnosis was
.15 ± 2.88 years. In the control group, none of the patients received
FX therapy, and were all treated with azathioprine and 5-ASA
he time of measurement; three patients also received systemic
teroids.
With regard to seasonal variability, 36 initiated treatment in the
inter (42.8%, mean age 14.6 ± 3 years) while 39 patients began
heir treatment during the summer (46.4%, mean age 14.7 ± 2.4
ears).
.2. Effect of IFX on PCDAI and IMPACT-III
PCDAI scores were assessed to monitor the efﬁcacy of IFX
nduction and maintenance therapy. PCDAI decreased signiﬁcantly
p < 0.001) during the treatment period when compared to the
nitial scores. The median PCDAI score was 35.0 (25th percentile
pc-25] 30; 75th percentile [pc-75] 42.5) at week 0 and decreased
o 10.0 (pc-25, -75: 1.3, 20) by week 6 (p < 0.0001). During main-
enance therapy, the PCDAI was 10.0 (pc-25, -75: 5, 20) and 5.0
pc-25, -75: 0, 25) at week 30 and week 53, respectively (p < 0.0001).
hen compared with the baseline, all changes in the IFX group
ere signiﬁcant.
After one year of IFX therapy, 33/50 of the IFX-treated children
ere in steroid-free remission (66%, PCDAI ≤ 12.5).
IMPACT-III scores were similarly improved after IFX treat-
ent with signiﬁcant differences at each monitoring time point
p < 0.0001). The median IMPACT-III score was 116.5 (pc-25, -75:
06.5, 131) at baseline and increased to 142 (pc-25, -75: 130, 149)
y week 6 (p < 0.0001). During the maintenance therapy period,
he IMPACT-III score was 140 (pc-25, -75: 129.5, 156.75) and 146
pc-25, -75: 127, 153.75) at week 30 and week 53, respectively
p < 0.0001).Fig. 1. Development of beta-crosslaps and osteocalcin medians during inﬂiximab
therapy course. bCL: beta-crosslaps; OC: osteocalcin.
3.3. Effect of IFX on bone markers
After IFX therapy, serum osteocalcin levels increased signif-
icantly (2 = 18.61, p < 0.001). A post hoc analysis revealed a
signiﬁcant change in the osteocalcin level from week 0 to week 6
(median 45.43; p < 0.004) and to week 30 (median 52.26; p = 0.001),
but not from week 0 to week 53 (median 37.67). While signiﬁcant
changes in osteocalcin levels were observed, we  did not observe
signiﬁcant changes in the serum bCL levels (p = 0.105) at any point
during the yearlong IFX treatment (Table 2 and Fig. 1).
When the osteocalcin and bCL levels of patients in the control
group were compared with those of IFX-treated patients, we  did
not observe signiﬁcant differences at the beginning (osteocalcin:
p = 0.6; bCL: p = 0.08) or end of the yearlong IFX treatment regimen
(osteocalcin: p = 0.66; bCL: p = 0.32), including only those patients
who were in remission (Table 2).
3.4. Vitamin D levels and seasonal variability of vitamin D
After one year of IFX treatment, there were no signiﬁcant dif-
ferences in the vitamin D level when the initial serum level prior
to treatment was compared to the endpoint serum level (p = 0.099;
Table 2).
The ratio of vitamin D deﬁciency to vitamin D insufﬁciency was
improved after the course of IFX therapy. The proportion of patients
with a vitamin D deﬁciency decreased from 57.4% at the onset of
the study to 40.0% after one year of IFX. When the study began, 18%
of patients had a serum vitamin D level >29 ng/mL, and this per-week 0 1 year
Fig. 2. Stratiﬁcations of vitamin D levels at baseline and after one year of inﬂiximab
therapy in paediatric patients with moderate to severe Crohn’s disease.
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Table 3
Effect of inﬂiximab therapy on bone mineral density in children with Crohn’s disease.
Week 0
Mean (±SD)
1 year
Mean (±SD)
Signiﬁcance
n = 29
Lumbar 2-4 Z-score −0.779 (±1.233) −0.728 (±1.566) p = 0.985
Body BMD Z-score −0.827 (±0.137) −0.872 (±0.138) p = 0.155
BMD: bone mineral density.
between the control and IFX patients in remission, no signiﬁcant
differences were observed at the study onset (p = 0.093) or study
conclusion (p = 0.042).
Seasonal variability was  assessed to determine if vitamin D
levels were inﬂuenced by the winter or summer period. Indeed, sig-
niﬁcant differences in the serum level of vitamin D were observed
between the summer and winter period at week 0 (p = 0.039). After
one year of IFX therapy, however, this signiﬁcance was no longer
apparent (p = 0.426). The median vitamin D values were 16.5 ng/mL
(pc-25, -75: 10.3, 20.77) and 20.6 ng/mL (pc-25, -75: 14.15, 27) at
week 0, and 18.1 ng/mL (pc-25, -75: 14.85, 24.7) and 23.6 ng/mL
(pc-25, -75: 17, 28.1) at week 53 in the winter and summer groups,
respectively. At the beginning of the study, 69% of patients were
severely deﬁcient and 19% of patients were insufﬁcient in the win-
ter period group, while the 48.6% of patients were deﬁcient and
28.6% were insufﬁcient in the summer period group. We  observed
an improved ratio of the vitamin D deﬁciency and insufﬁciency in
both groups after one year of IFX treatment (Fig. 3).
3.5. Effects of IFX on bone mineral density
Prior to initiation of IFX treatment, 18.3% of the children in the
IFX group had a reduced lumbar BMD  Z-score (BMD Z-score < −2.0).
In 29/50 cases, repeated DEXA results were available. When this
subset of patients was analysed, there were no signiﬁcant changes
in BMD  Z-scores over time (lumbar and total body BMD  Z-scores
were p = 0.985, and p = 0.155, respectively) (Table 3).
3.6. Results of the correlation analysis
A Spearman correlation analysis indicated a weak negative cor-
relation between the vitamin D level and the PCDAI at week 0
( = −0.303) and at week 53 ( = −0.26), and between the vita-
min  D and osteocalcin levels at week 0 ( = −0.241) and week 6
( = −0.315).
4. Discussion
In this study, we  conﬁrmed the beneﬁcial effect of a yearlong IFX
therapy course on the clinical status (decreased PCDAI, improved
IMPACT-III), and thus QoL, of paediatric patients with moderate to
severe CD. Despite favourable clinical changes, we did not observe
signiﬁcant improvement in the BMD  Z-score after one year of treat-
ment. Similarly, there were no signiﬁcant differences in serum bCL
levels or vitamin D levels. Treatment with IFX, however, was asso-
ciated with a signiﬁcant increase in serum levels of osteocalcin.
The goal of this study was to determine whether bone biomarker
levels and BMD  were affected by one year of IFX therapy in
children with moderate to severe CD. Osteocalcin, a marker of
bone osteoblast activity, improved signiﬁcantly over the course
of IFX therapy, with the exception of week 53. Serum bCL levels
did not change signiﬁcantly. While decreases in disease activity
(lower PCDAI score) could give rise to favourable changes in bone
metabolism, our correlation analysis did not support this relation-
ship in the present study. When compared with the control group,
there were no signiﬁcant differences in bone marker levels between
the two therapy types (IFX vs. standard). Future studies should
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0%
20%
40%
60%
80%
100%
mme
>29 ng/ml
20-29 ng/ml
20 ng/ml≤
ar of 
i
r
a
c
o
I
b
t
c
t
t
i
I
m
o
g
I
o
[
w
(
h
i
b
B
o
p
a
v
o
m
a
r
a
a
[
h
o
a
r
t
t
I
r
IWinter, week 0 Winter, 1 year Su
Fig. 3. Stratiﬁcations of vitamin D level at baseline and after one ye
nvestigate how BMD, osteocalcin and bCL are affected by “deep
emission” to understand the relationship of bone health to CD. In
dult CD patients, Miheller and colleagues also observed a signiﬁ-
ant increase in osteocalcin levels after IFX therapy [24]. Similar to
ur study, no signiﬁcant changes in bCL levels were observed [24].
n a subset of the REACH study, bone formation markers (serum
one speciﬁc alkaline phosphatase and N-terminal propeptide of
ype 1 collagen) and resorption (urine C-telopeptide of collagen
ross-links and deoxypyrodinoline) changed signiﬁcantly, though
his result included only the induction therapy period and no long-
erm data [25]. While a recent study reported signiﬁcant changes
n the anthropometry quality of children throughout a one year
FX course, they did not observe changes in biomarkers of bone
etabolism of BMD  [26].
In our study, BMD  Z-scores were not signiﬁcantly different after
ne year of IFX therapy. A reduction in bone mineral mass per age
roup was detected in 18% of patients at the onset of the study.
n an Italian study, Paganelli and colleagues reported that 31.4%
f the CD patients in the study had a low BMD  (Z-score ≤ −2)
7]. Another population-based study in children and adolescents
ith IBD showed that almost 50% of patients had decreased BMD
Z-score ≤ −1), while approximately 25% of the study population
ad a low BMD  (Z-score ≤ −2) [27].
Our results, as well as data from the literature, highlight the
mportance of routine patient follow up and improvement of
one metabolism, since improvement of BMD  cannot be assumed.
ecause peak bone mass is achieved during childhood, ﬁnding an
ptimal treatment to maintain/improve bone health is essential in
aediatric CD patients.
Because vitamin D plays roles in immune system regulation in
ddition to its roles in bone health and homeostasis, monitoring
itamin D levels should be an important aspect in the treatment
f CD [28,29]. Thus, ensuring patients have adequate serum vita-
in  D levels may  further increase the efﬁcacy of treatment in IBD,
s a previous study revealed [30]. A recently published review
eported that low vitamin D levels were a global problem in all
ge groups [16]. In a survey from the United States, 35.8% paedi-
tric IBD patients had a serum vitamin D concentration ≤15 ng/mL
13]. Similarly, Levin et al. reported that 19% of children with IBD
ad a vitamin D deﬁciency while 38% had an insufﬁciency [31]. In
ur study, 57% and 25% of the patients had vitamin D deﬁciency
nd insufﬁciency, respectively, prior to IFX therapy initiation. Our
esults have a higher incidence of deﬁciency and insufﬁciency due
o the threshold selected for our study versus the threshold applied
o the previous studies [22].Little data is currently available on the correlation between
FX and vitamin D levels. The study from Pichler and colleagues
eported a signiﬁcant increase in vitamin D level as result of
FX therapy [26]. Yet a recent study found that 1,25-dihydroxyr, week 0 Summer, 1 year
inﬂiximab treatment with regard to season of treatment initiation.
vitamin D serum concentrations were increased without concomi-
tant changes in 25-hydroxy vitamin D after IFX induction therapy.
The stable 25-hydroxy vitamin D levels indicate that the increases
in 1,25-hydroxy vitamin D levels were not due to improved gut
absorption of vitamin D but rather may  be due to the suppressive
effect of inﬂammation on renal activation of vitamin D [32].
When IFX-treated CD patients in remission were compared with
the control group, clinical remission did not signiﬁcantly improve
serum vitamin D levels. Future studies should investigate whether
patients in ‘deep remission’ show different correlations with vita-
min  D levels.
The suggested vitamin D intake in healthy children is 600 U/day.
The Endocrine Society recommends a dose of 2000 U/day for at
least six weeks in patients with a deﬁciency. In the present study,
patients received a 1000 U/day vitamin D supplementation for ≥15
months. In future studies, a higher dose (2000 U/day) might be rec-
ommended, though in inﬂammatory conditions such as IBD the
vitamin D level is inﬂuenced by several mechanisms (e.g. intestinal
absorption). Thus, the effect of an increased dose on serum vitamin
D levels is difﬁcult to predict.
When patient vitamin D levels were analysed with respect to
therapy initiation season, patients who initiated IFX during the
summer months had a signiﬁcantly higher vitamin D level. At base-
line, 22% of patients that initiated treatment during the summer
season had vitamin D serum levels >29 ng/mL, as compared to 11.5%
of patients who began treatment in the winter months. Severe
vitamin D deﬁciency was observed in more than 69% of patients
in the winter group and nearly 50% of patients in the summer
group at the onset of treatment. While vitamin D levels did not
change signiﬁcantly after one year of IFX, the ratio of vitamin D
deﬁciency (<20 ng/mL) decreased regardless of the season. These
ﬁndings suggest that IFX may  reduce the seasonal variability of
vitamin D levels during treatment. In the winter group, vitamin
D levels did not decrease, and we observed an increasing trend
during IFX treatment. Although signiﬁcant long term improvement
in vitamin D levels was  not observed after IFX administration,
decreases in vitamin D levels during the winter season did not
occur, though the nature of the relationship between vitamin D
and IFX is not yet understood. Previous studies have also reported
an effect of seasonality of vitamin D levels in IBD. McCarthy and
colleagues found lower vitamin D concentrations in CD patients
than in control subjects during both seasons. Moreover, lower
vitamin D concentrations were observed during late winter com-
pared to late summer both in CD patients and healthy controls.
The authors also found that patients receiving vitamin D supple-
mentation did not have seasonal variation [17]. In contrast, other
studies have not identiﬁed a signiﬁcant association between vita-
min  D level and seasonality in patients with ulcerative colitis or IBD
[33].
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In summary, IFX therapy demonstrated a clear clinical beneﬁt
n paediatric patients with moderate to severe CD. Moreover, the
ddition of IFX therapy improved bone health initially, though this
eneﬁcial effect was diminished after one year of treatment. More-
ver, despite supplemental administration of the vitamin D and
alcium, low vitamin D levels in CD patients persisted. Seasonal
ariability of vitamin D levels was observed prior to IFX initiation
ut these differences were no longer apparent after one year of IFX
reatment. We  did not observe an exclusive inﬂuence of IFX therapy
n bone metabolism and vitamin D levels.
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